On this study, we investigated cognitively unimpaired and cognitively impaired individuals and how plasma P-tau217 can improve the cost-efficiency in clinical trials. So we evaluated three different thresholds and we evaluated how the use of plasma P-tau217 could reduce the number of amyloid PETs that would be required in a clinical trial, also the cost and the time that it would take to do a trial using plasma P-tau217 as a pre-screening method...
On this study, we investigated cognitively unimpaired and cognitively impaired individuals and how plasma P-tau217 can improve the cost-efficiency in clinical trials. So we evaluated three different thresholds and we evaluated how the use of plasma P-tau217 could reduce the number of amyloid PETs that would be required in a clinical trial, also the cost and the time that it would take to do a trial using plasma P-tau217 as a pre-screening method. And what we found that for both cognitively unimpaired and impaired individuals, using an intermediate threshold would be the best one because it would reduce the number of amyloid PETs, but not increase that much the time of recruitment. And also would have a similar reduction on cost as using a higher threshold that on our study we call the conservative. The problem of the conservative is that it would increase a lot the time of recruitment because when you use a very high threshold you need to screen more people to include in your trial, so in the end we found that yes, using plasma P-tau217 can improve the cost-efficiency on a clinical trial because you would, when you do the plasma test, recruit people that are more likely to have amyloid pathology, you decrease the number of amyloid PETs that you would have to do. And in the end, this will reduce cost. That’s something very important also on the trials, not increasing a lot the time compared to a trial that was not doing a pre-screening with plasma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
